Global Intellectual Property Specialists

Strategic global thinking for the pharmaceutical and biopharmaceutical industries

Our Capabilities

We use our global experience to support life sciences clients from early R&D to commercial launch, and beyond.

Explore our BioBlast®

View our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date.

Our People

Our lawyers and attorneys have science backgrounds, were trained at top tier firms, and most have experience in-house at multinational giants.

Award-winning IP services

Ranked internationally and domestically, our pharmaceutical, biopharmaceutical and life sciences focussed lawyers and attorneys are recognised as being among the best IP practitioners in the world.

Our Capabilities

Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys, to the pharmaceutical, biopharmaceutical and life sciences industries.

We coordinate and execute local and multi-jurisdictional IP litigation strategies, provide IP/legal support for regional and global business development activities and licensing deals, and prosecute patent and trade mark applications around the world.

Patent: Legal and Attorney Services

Trade Mark: Legal and Attorney Services

Commercial IP Services

Regulatory Affairs Services

View our Capabilities

Since its establishment in 2017 boutique Pearce IP has dominated in the area of pharmaceutical patents. Thanks to its deep bench of talented professionals, any life sciences brief is dispatched with alacrity and poise.

IAM Patent 1000, 2024

IP SPECIALISTS LAWYERS – PATENT ATTORNEYS – TRADE MARK ATTORNEYS

Our Leaders

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)

Adele Chadwick

Executive, Deputy CEO & Head of Talent

Paul Johns

Executive, Lawyer (Head of Litigation - New Zealand)

Chris Vindurampulle PhD

Executive, Patent & Trade Mark Attorney (Head of Patent Prosecution)

Kimberley Evans

Executive, Lawyer & Trade Mark Attorney (Head of Trade Marks)

Chris Coates (Maj Ret)

Executive, Finance

Helen Macpherson

Executive, Lawyer (Head of Litigation - Australia)

PEARCE IP BLOG

Read our latest updates & insights

Pearce IP BioBlast® for the fortnight ending 11 October 2024

by Naomi Pearce, Chantal Savage, Nathan Kan | Oct 14, 2024

Aflibercept 8 October 2024 | AU | Bayer’s High Dose Eylea® (Aflibercept) PFS Approved in Australia On 8 October 2024,...

Soft Close, Hard Lessons: Full Court Reinforces Purposive Construction of Patent Claims and the Disclosure Requirements for Divisional Patents

by Naomi Pearce, Helen Macpherson, Nathan Kan | Oct 11, 2024

On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).